iBio Inc. Showcases Innovative Antibody Developments Soon

Author: Olivia Taylor Updated: 10-21-2025 07:17 AM

Exciting Presentations from iBio Inc.

iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his upcoming oral presentation at ObesityWeek 2025, scheduled for November 4-7. This event will take place in Atlanta, focusing on innovative strategies to combat obesity.

Innovative Data from Research

The highlight of Schwartz's presentation will be data from their extensive non-human primate study of IBIO-610, an Activin E antagonist antibody. This data is pivotal as it underscores the potential of this antibody to offer a unique approach to treating obesity. As Dr. Brenner, iBio's CEO and Chief Scientific Officer, stated, the findings suggest that inhibiting Activin E signaling may facilitate fat-selective weight loss. It may also support long-term weight maintenance and enhance the effectiveness of GLP-1 therapies, ultimately aiming to transform treatment paradigms for cardiometabolic disorders.

Details of the ObesityWeek Presentation

Presentation Title: Discovery and Testing of a First-in-Class Activin E Antagonist Antibody for the Treatment of Obesity
Date: November 4, 2025
Time: 2:00 p.m. – 2:15 p.m. EST
Location: A411-A412

Poster Presentation

In addition to the oral presentation, Dr. Schwartz will also showcase a poster titled "Preclinical Evaluation of a Long-Acting Anti-Myostatin Therapy for Obesity" on November 5 at 2:30 p.m. EST, further expanding on innovative approaches in obesity treatment.

PEGS Europe Presentation Details

Martin Brenner will also be presenting at PEGS Europe 2025 from November 11-13 in Lisbon. His presentation focuses on the efficacy of IBIO-610 in inducing fat-selective weight-loss in diet-induced obese mice.

Presentation Details

Title: A First-in-Class Anti-Activin E Antibody Induces Fat-Selective Weight-Loss in Diet-Induced Obese Mice
Date: November 12, 2025
Time: 11:45 a.m. – 12:15 p.m. WET
Location: Podium Presentation

About iBio Inc.

iBio (NASDAQ: IBIO) is an innovative biotechnology firm leveraging artificial intelligence and computational biology to create next-generation biopharmaceuticals targeting various challenging diseases including obesity and cancer. Their proprietary 3D modeling enhances drug discovery processes, leading to significant advancements in antibody therapies aimed at fulfilling unmet medical requirements. iBio seeks to revolutionize the drug discovery timeline while promoting precision medicine.

Corporate Contact Information

Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com

Frequently Asked Questions

What is the focus of iBio's upcoming presentations?

iBio will be presenting its research on the Activin E antibody, highlighting its implications for obesity treatment.

Where will these presentations be held?

The presentations are scheduled for ObesityWeek 2025 in Atlanta and PEGS Europe 2025 in Lisbon.

Who will present on behalf of iBio?

Cory Schwartz, Ph.D. will present at ObesityWeek, while Martin Brenner will present at PEGS Europe.

What is IBIO-610?

IBIO-610 is an Activin E antagonist antibody being studied for its potential to promote fat-selective weight loss.

How does iBio aim to enhance treatment for obesity?

iBio focuses on innovative approaches through advanced antibody therapies that target metabolic pathways involved in obesity.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.